Stockreport

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p Generally well tolerated with no impact on cornea [Read more]